With conventional drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain, there may be value in exploring plants associated with traditional medicines to discover new drug molecules and mixtures. Gb Sciences is connecting plant-based medicine with modern in silico drug discovery tools, leveraging a unique AI-enabled platform to mine plant species to uncover minimum essential mixtures of molecules with therapeutic benefits and reduced side effect profiles. The company’s President, Andrea Small-Howard, Ph.D., sat down to discuss Gb’s evolution from a cannabis company to a plant-inspired biopharmaceutical company and what makes their approach truly unique, with Pharma’s Almanac’s David Alvaro, Ph.D.
